Clin Mol Hepatol > Volume 28(1); 2022 > Article |
|
Study | Study type | Quality assessment tool | Study score | Total possible score |
---|---|---|---|---|
Herath et al. [12] (2019) | Cross-sectional | Newcastle-Ottawa scale* | 8 | 10 |
Hagström et al. [13] (2016) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Sarkar et al. [14] (2020) | Cohort study | Newcastle-Ottawa scale | 8 | 8 (1× question is not applicable) |
Mousa et al. [15] (2018) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Page et al. [16] (2011) | Case series | MOGA/IHE quality appraisal tool | 10 | 15 (3× question is not applicable) |
De Souza et al. [5] (2016) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Jung et al. [20] (2020) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Sattari et al. [17] (2020) | Cohort study | Newcastle-Ottawa scale | 6 | 9 |
Rosenbluth et al. [18] (2020) | Cohort study | Newcastle-Ottawa scale | N/A† | N/A† |
Ali et al. [19] (2018) | Cohort study | Newcastle-Ottawa scale | N/A† | N/A† |
Liu et al. [22] (2013) | Cross-sectional | Newcastle-Ottawa scale* | 8 | 9 (1× question is not applicable) |
Forbes et al. [6] (2011) | Cohort study | Newcastle-Ottawa scale | 8 | 9 |
Ajmera et al. [7] (2016) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Wang et al. [23] (2021) | Case-control | Newcastle-Ottawa scale | 6 | 9 |
Lu et al. [24] (2017) | Cross-sectional | Newcastle-Ottawa scale* | 10 | 10 |
Golabi et al. [25] (2018) | Cross-sectional | Newcastle-Ottawa scale* | 7 | 10 |
Ryu et al. [26] (2015) | Cohort study | Newcastle-Ottawa scale | 6 | 9 |
Bruno Ade et al. [27] (2014) | Cross-sectional | Newcastle-Ottawa scale* | 8 | 9 (1× question is not applicable) |
Lee et al. [8] (2019; LGA study) | Cohort study | Newcastle-Ottawa scale | 6 | 9 |
Lee et al. [21] (2019; GDM study) | Cohort study | Newcastle-Ottawa scale | 7 | 9 |
Liu et al. [28] (2013) | Cross-sectional | Newcastle-Ottawa scale* | 8 | 10 |
Kubihal et al. [9] (2021) | Cross-sectional | Newcastle-Ottawa scale* | 9 | 10 |
Individual study quality assessments, observational studies were assessed using the Newcastle-Ottawa scale whilst case series were assessed by the MOGA/IHE quality appraisal tool.
N/A, not applicable.
The prevalence was based on the random effects model. Prevalence data of the overall pooled data relating to pregnancy related outcomes in the metaanalysis.
NAFLD, non-alcoholic fatty liver disease; ER, event rate; CI, confidence interval; GDM, gestational diabetes mellitus; DM, diabetes mellitus; GHTN, gestational hypertension; HELLP, haemolysis, elevated liver enzymes, low platelet count; BMI, body mass index; LSCS, low section caesarean section; LGA, large for gestational age birth; IUGR, intrauterine growth restriction; PPH, post-partum haemorrhage; Para 1, second pregnancy; Para ≥2, 3rd or later pregnancy; LBW, low birth weight; NASH, non-alcoholic steatohepatitis; NAFL, non alcoholic fatty liver.
Study | Exclusion of significant alcohol consumption | Exclusion of other causes of hepatic steatosis | Absence of coexisting chronic liver disease | Demonstration of hepatic steatosis by imaging or biopsy | Satisfied NAFLD Criteria were met |
---|---|---|---|---|---|
Herath et al. [12] (2019) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Hagström et al. [13] (2016) | Not reported | Not reported | Not reported | Not reported | Unknown |
Sarkar et al. [14] (2020) | Not reported | Not reported | Not reported | Not reported | Unknown |
Mousa et al. [15] (2018) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Page et al. [16] (2011) | Yes | Yes | Yes | Imaging (4/5 patients) or Histology (1/5 patients) | Yes |
De Souza et al. [5] (2016) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Jung et al. [20] (2020) | Yes | No | Yes | Imaging (USAB) | Unknown |
Sattari et al. [17] (2020) | Not reported | Not reported | Yes | Imaging (USAB) | Unknown |
Liu et al. [22] (2013) | Yes | Not reported | Yes | Imaging | Unknown |
Forbes et al. [6] (2011) | Not reported | Not reported | Not reported | Imaging | Unknown |
Ajmera et al. [7] (2016) | Yes | Yes | Not reported | Imaging (CT scan) | Unknown |
Wang et al. [23] (2021) | Not reported | Not reported | Not reported | Not reported | Unknown |
Lu et al. [24] (2017) | Yes | Not reported | Yes | Imaging (USAB) | Unknown |
Golabi et al. [25] (2018) | Yes | Not reported | Yes | Imaging (USAB) | Unknown |
Ryu et al. [26] (2015) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Bruno Ade et al. [27] (2014) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Lee et al. [8] (2019; LGA study) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Lee et al. [21] (2019; GDM study) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Liu et al. [28] (2013) | Yes | Partial | Not reported | Imaging (USAB) | Unknown |
Kubihal et al. [9] (2021) | Yes | Yes | Yes | Imaging (USAB) | Yes |
Hydar El Jamaly
https://orcid.org/0000-0002-8591-2548
The growing burden of non-alcoholic fatty liver disease on mortality2023 April;29(2)
Nonalcoholic fatty liver disease and non-liver comorbidities2023 February;29(Suppl)